• At the 2026 ASCO meeting, GRAIL reported full NHS-Galleri and PATHFINDER 2 results showing its Galleri blood test increased screen-detected cancers and reduced late-stage diagnoses when added to standard screenings in large North American and UK populations.
• The data highlighted high specificity, relatively strong positive predictive value, and accurate cancer signal origin detection, suggesting Galleri could materially change how health systems approach multi-cancer screening while maintaining a favorable safety profile.
• We’ll now examine how these large-scale results on earlier-stage detection and reduced Stage IV cancers could reshape GRAIL’s investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.

GRAIL Investment Narrative Recap

To own GRAIL, you have to believe Galleri can become a standard add-on to routine cancer screening, supported by convincing real-world data and eventual broad reimbursement. The new NHS-Galleri and PATHFINDER 2 readouts strengthen the clinical case for earlier detection and fewer late-stage cancers, but they do not remove the near term overhang of heavy losses and cash burn or the key catalyst of securing favorable FDA, Medicare, and payer decisions.

Among the recent updates, the completion of GRAIL’s PMA submission for Galleri to the FDA looks especially important in light of these ASCO data. The combination of randomized NHS-Galleri results and registrational PATHFINDER 2 performance could be central to how regulators, Medicare (under the new MCED coverage pathway), and private payers judge clinical utility and coverage, shaping how quickly test volumes and screening revenue might scale if the evidence is viewed as sufficiently compelling.

Yet, despite the clinical momentum, investors should also be aware that the NHS-Galleri trial’s missed primary endpoint could still weigh on how regulators, payers, and guidelines bodies ultimately view...

GRAIL's narrative projects $310.9 million revenue and $41.1 million earnings by 2029.

Uncover how GRAIL's forecasts yield a $67.71 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were penciling in about US$343 million of revenue and a swing to roughly US$54 million of earnings by 2029, so these new ASCO results could either reinforce their view that strong evidence will unlock broad coverage, or force a rethink if concerns about the missed primary endpoint and regulatory outcomes grow.

Explore 5 other fair value estimates on GRAIL - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your GRAIL research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free GRAIL research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate GRAIL's overall financial health at a glance.

No Opportunity In GRAIL?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 46 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.